SUNESIS PHARMACEUTICALS, INC

SUNESIS PHARMACEUTICALS, INC

Sunesis is a clinical-stage biopharmaceutical company focused on the development and commercialization of new oncology therapeutics.

Sunesis Pharmaceuticals, Inc_logo

Industry:
Organization

Country:
United States

Phone:
650 266 3500

Market Cap:
96.33M
Total Revenue:
120k
Total Assets:
23.25M
Total Cash:
20.41M

Phone:
(650) 266-3500

Followers:
58

Location:
395 Oyster Point Boulevard Suite 400, South San Francisco, CA, 94080, California

Website Url:
http://www.sunesis.com



Financial & Stock
Exchange NasdaqGS. Currency in USD. Market state POSTPOST
According to Sunesis Pharmaceuticals, Inc's financial reports the company's revenue in 2020 were 120k an decrease(-94%) over the years 2019 revenue that were of 2.07M. In 2020 the company's total earnings were -21.61M while total earnings in 2019 were -23.33M(-8.7%).
Company's stock symbol is SNSS. Lastest price : 5.32. Total volume :70.24M Click reload if you want to check the lastest price on market!!!


Site Inspections: http://www.sunesis.com

Unable to get host informations!!!

Loading ...
Loading ...


More informations about "Sunesis Pharmaceuticals, Inc" on Search Engine

Sunesis Pharmaceuticals, Inc. (SNSS) Stock Price, News

Finance.yahoo.com Sunesis Pharmaceuticals Inc (NASDAQ: SNSS) merger partner, Viracta Therapeutics Inc announces that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent...

Sunesis Pharmaceuticals, Inc. (SNSS) Stock Price, News

Finance.yahoo.com Search for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on …

Overview | Sunesis Pharmaceuticals, Inc.

Sunesis.gcs-web.com The Investor Relations website contains information about Sunesis Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.

Viracta Therapeutics Announces Closing of Merger with

Finance.yahoo.com Feb 25, 2021 · Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, …

SNSS | Sunesis Pharmaceuticals Inc. Profile | MarketWatch

Marketwatch.com Sunesis Pharmaceuticals Inc. company facts, information and financial ratios from MarketWatch.

SNSS Stock Forecast, Price & News (Sunesis Pharmaceuticals)

Marketbeat.com Sunesis Pharmaceuticals' mailing address is 395 OYSTER POINT BOULEVARD SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-266-3500 or via email at [email protected]

Viracta Therapeutics Announces Closing of Merger with

Markets.businessinsider.com Feb 25, 2021 · SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of …

Sunesis Pharmaceuticals Announces Clinical Update on

Globenewswire.com Jun 23, 2020 · Sunesis is a biopharmaceutical company developing novel targeted inhibitors for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug development …

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Reveals Plan

Biopharmajournal.com Jul 06, 2020 · Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) recently announced that it will not conduct a Phase 2 clinical trial of its vecabrutinib contrary to previously announced plans. The biopharma revealed that its vecabrutinib Program will not be advancing to the earlier planned Phase 2 stage expected to follow the Phase 1b/2 clinical trial.

Home - Viracta Therapeutics, Inc.

Viracta.com Apr 08, 2021 · ABOUT US We are a clinical-stage, biomarker-directed precision oncology company focused on advancing new medicines for the treatment of virus-associated malignancies.

Sunesis Jumps on Merger Deal with Viracta Therapeutics

Thestreet.com Nov 30, 2020 · Sunesis Pharmaceuticals - Get Report shares jumped on Monday after the biotech said it was merging with Viracta Therapeutics, a privately held precision oncology company.

Viracta Therapeutics Announces Closing of Merger with

Bloomberg.com Feb 25, 2021 · Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement Shares of Viracta to commence trading on …

Sunesis Pharmaceuticals, Inc. - TheStreet

Thestreet.com Nov 30, 2020 · SUNESIS INVESTOR ALERT By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Merger Of Sunesis Pharmaceuticals, Inc. - SNSS By Business Wire Dec 29, 2020 5:56 PM EST

Sunesis Pharmaceuticals, Inc. (SNSS) Institutional

Nasdaq.com Find the latest Institutional Holdings data for Sunesis Pharmaceuticals, Inc. (SNSS) at Nasdaq.com.

Sunesis Pharmaceuticals, Inc.

Ir.sunesis.com Sunesis Pharmaceuticals, Inc. (“Sunesis”) and Viracta Therapeutics, Inc. (“Viracta”) have entered into an Agreement and Plan of Merger and Reorganization, dated November 29, 2020, as may be amended from time to time (the “Merger Agreement”), pursuant to which a wholly owned subsidiary of Sunesis will merge with and into Viracta ...

Sunesis Pharmaceuticals - Home | Facebook

Facebook.com Sunesis Pharmaceuticals to Provide Program Update for Non-Covalent BTK-Inhibitor Vecabrutinib at Analyst & Investor Event during ASH 2018 | Sunesis Pharmaceuticals, Inc. The Investor Relations website contains information about Sunesis Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.

Sunesis Pharmaceuticals, Inc. Investigation – Weiss Law LLP

Weisslawllp.com Sunesis Pharmaceuticals, Inc. Investigation We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Sunesis Pharmaceuticals, Inc. (“Sunesis ” or the “Company”) (NASDAQ: SNSS) in connection with the Company’s proposed merger with privately-held Viracta Therapeutics, Inc ...

Sunesis Pharmaceuticals Inc (SNSS) Stock Price History

Wallmine.com Sunesis Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Sunesis Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – SNSS Thursday, 3 September 2020

Sunesis Pharmaceuticals Inc. (SNSS) can’t be written off

Investchronicle.com Feb 24, 2021 · Sunesis Pharmaceuticals Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $5.55 on 02/23/21, with the lowest value was $1.97 for the same time period, recorded on 01/04/21. Sunesis Pharmaceuticals Inc. (SNSS) full year performance was -53.48%

For Sunesis Pharmaceuticals Inc. [SNSS], Analyst sees a

Dbtnews.com Feb 24, 2021 · Sunesis Pharmaceuticals Inc.’s Net Margin is presently recorded at -1125.42. Return on Total Capital for SNSS is now -103.01, given the latest momentum, and Return on Invested Capital for the company is -146.69. Return on Equity for this stock declined to …

Viracta Therapeutics, Inc. (VIRX) Stock Price Today, Quote

Seekingalpha.com Jun 27, 2018 · Sunesis Pharmaceuticals, Inc. Craters On Negative VALOR Data. Stock Is Now A Terminal Short EnhydrisPECorp Wed, Oct. 08, 2014 3 Comments Sunesis Pharmaceuticals, Inc. Offers A Moderate Risk 80%...

Sunesis Pharmaceuticals, Inc. (SNSS): Price and Financial

Stocknews.com Revenue growth over the past 12 months for Sunesis Pharmaceuticals Inc comes in at -94.21%, a number that bests merely 1.03% of the US stocks we're tracking. If you're looking for stocks that are quantitatively similar to Sunesis Pharmaceuticals Inc, a group of peers worth examining would be ADXS, CRDF, ONCT, PROF, and AVEO.

Sunesis Pharmaceuticals, Inc. | LinkedIn

Linkedin.com Sunesis Pharmaceuticals, Inc. | 2,113 followers on LinkedIn. Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the ...

Viracta | Investor Relations - Welcome

Viracta.investorroom.com Investor Relations. Viracta is a precision oncology company targeting virus-associated malignancies. The Company's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in …

Sunesis Pharmaceuticals - Crunchbase Company Profile & Funding

Crunchbase.com Sunesis is an emerging biopharmaceutical company creating new medicines to improve the lives of people with cancer. They are building a pipeline of drugs that selectively block critical mechanisms required for tumor growth and survival.

Sunesis Stock Price (VIRX) - Investing.com

Investing.com Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development of targeted inhibitors for the treatment of hematologic and …

Sunesis Pharmaceuticals Inc. [SNSS] is 38.19% higher this

Dbtnews.com Jan 13, 2021 · Sunesis Pharmaceuticals Inc. [NASDAQ: SNSS] gained 15.55% or 0.37 points to close at $2.75 with a heavy trading volume of 2562540 shares. The company report on January 9, 2021 that MERGER INVESTIGATION: Halper Sadeh LLP Investigates CPAH, HMSY, SNSS, EIDX; Shareholders Are Encouraged to Contact the Firm.. Get the hottest stocks to trade every day before the market …

SEC Filing | Sunesis Pharmaceuticals, Inc.

Ir.sunesis.com Mar 24, 2006 · South San Francisco, CA, March 24, 2006 – Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics, today reported financial results for the quarter and fiscal year ended December 31, 2005.

Sunesis Pharmaceuticals Inc - Law Insider

Lawinsider.com Sunesis Pharmaceuticals Inc – VIRACTA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT (January 13th, 2021)

SNSS Stock: Why Sunesis Pharmaceuticals Is Soaring Today

Investorplace.com Feb 23, 2021 · Sunesis Pharmaceuticals (NASDAQ: SNSS) is up more than 20% in trading today after analysts at Oppenheimer upgraded the stock to “outperform.”Those analysts set a …

Viracta Therapeutics, Inc. 10-K Feb. 24, 2021 6:06 AM

Seekingalpha.com Sunesis is a biopharmaceutical company focused on the development of novel targeted inhibitors for the treatment of hematologic and solid cancers. Sunesis is developing SNS-510, a PDK1 inhibitor...

SNSS Stock Price Increased Over 65% Intraday: Why It Happened

Pulse2.com Feb 24, 2021 · The stock price of Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) increased by over 65% during intraday trading. This is why it happened. The stock price of Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) increased by over 65% during intraday trading as it went from a previous close of $4.28 to a day high of $7.09.

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Jumps 20.22%

Stocksregister.com Feb 24, 2021 · To see how Sunesis Pharmaceuticals, Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: SNSS stock’s performance was +20.22% in the latest trading, and -53.48% in the past year, while Bristol-Myers Squibb Company (BMY) has traded -0.44% on the day and positioned -5.08% lower than it was a year ago.

Viracta | Investor Relations - News Releases

Viracta.investorroom.com Apr 08, 2021 · Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company management will present at the 20th Annual... Mar 23, 2021. Viracta and XOMA Announce Multi-License Milestone and Royalty Monetization Transaction.

SNSS | Sunesis Pharmaceuticals Inc. Options | MarketWatch

Marketwatch.com May 30, 2020 · Sunesis Pharmaceuticals Inc. historial options data by MarketWatch. View SNSS option chain data and pricing information for given maturity periods.

Sunesis Pharmaceuticals Inc. - Company Profile - BCIQ

Bciq.biocentury.com ...AML therapy from Sunesis Denovo Biopharma LLC gained global rights to vosaroxin (now DB106) from Sunesis Pharmaceuticals Inc.....cell therapy against CD19 (KTE-X19, KTE-C19) Bristol-Myers Squibb Co. Acceleron Pharma Inc. argenx S.E. Alkermes plc Gilead Sciences Inc. Denovo Biopharma LLC Sunesis Pharmaceuticals Inc....

Sunesis Pharmaceuticals Inc. (SNSS) upgraded Issued by

Newsheater.com Feb 24, 2021 · Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) went up by 17.98% from its latest closing price compared to the recent 1-year high of $11.30. The company’s stock price has collected 7.55% of gains in the last five trading sessions. Press Release reported on 02/16/21 that Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its …

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Expected to

Theenterpriseleader.com Feb 27, 2021 · Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) – Analysts at Oppenheimer raised their FY2021 earnings per share (EPS) estimates for shares of Sunesis Pharmaceuticals in a research note issued to investors on Tuesday, February 23rd. Oppenheimer analyst H. Singh now anticipates that the biopharmaceutical company will post earnings of ($0.30) per share for the year, up from their […]

Sunesis Pharmaceuticals, Inc. (SNSS) has great growth

Marketingsentinel.com Jan 13, 2021 · Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has a beta value of 2.29 and has seen 2,556,501 shares traded in the last trading session. The company, currently valued at $49.76 Million, closed the last trade at $2.75 per share which meant it gained $0.37 …

SNSS Stock Price Increased Over 46% Intraday: Why It Happened

Pulse2.com Feb 23, 2021 · The stock price of Sunesis Pharmaceuticals, Inc (NASDAQ: SNSS) increased by over 46% during intraday trading. This is why it happened. The stock price of Sunesis Pharmaceuticals, Inc (NASDAQ: SNSS) increased by over 46% during intraday trading as it went from a previous close of $3.56 to a day high of $5.20.

SUNESIS PHARMACEUTICALS INC : Completion of Acquisition or

Marketscreener.com Feb 24, 2021 · Item 2.01. Completion of Acquisition or Disposition of Assets. On February 24, 2021, Sunesis Pharmaceuticals, Inc. (the "Company") completed its business combination with Viracta Therapeutics, Inc. ("Viracta"), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated November 29, 2020, by and among the Company, Sol Merger Sub, Inc. …

Are Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Shares

Marketingsentinel.com Jan 20, 2021 · Sunesis Pharmaceuticals, Inc. share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen +0.32 percent over the past six months and at a 87.41% annual growth rate that is well above the industry average of 14.3%.

SUNESIS PHARMACEUTICALS, INC. (NASDAQ:SNSS) Files An 8-K

Marketexclusive.com Dec 17, 2019 · Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of …

Sunesis Pharmaceuticals Inc - Dividend.com

Dividend.com Sunesis Pharmaceuticals Inc (SNSS) Payout Estimation Logic Estimates are provided for securities with at least 5 consecutive payouts, special dividends not included.

Ward Wolff - Member Board Of Directors - Sunesis

Linkedin.com Sunesis Pharmaceuticals, Inc. Feb 2018 - Present 3 years 3 months. Member Board Of Directors Calithera Biosciences Dec 2014 - Present 6 years 5 months. Member - Board of Directors ...

Is Sunesis Pharmaceuticals, Inc. (SNSS) a Stock to Watch

Investorsobserver.com Nov 30, 2020 · Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute ...

- SNSS - Stock Price Today - Zacks

Zacks.com May 03, 2019 · Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for …

Sunesis Pharma - Venrock

Venrock.com Sunesis Pharmaceuticals discovers and develops novel small molecule therapeutics for important diseases, with a primary focus on the regulation of protein-protein and small molecule-protein interactions as well as other enzymes.

Viracta Therapeutics Inc - Company Profile and News

Bloomberg.com Viracta Therapeutics, Inc. is a clinical-stage oncology company. The Company focuses on advancing new medicines for the treatment of virus-associated malignancies.